The pharmaceutical industry has been a soft target for many years. Attacks by journalists, politicians, and the lay public tend to be triggered by publications with which professional medical writers are associated. Fault is found, either in the content, perceived obfuscation of content, or on perceived deceptive authorship practices. The term ‘ghostwriter’ is used with great frequency and is often misapplied, or ill-defined (if it is defined, at all). For the most part, these criticisms have gone unanswered. We must understand that we represent the potential for the strongest and most influential voice in refuting misinformation and misunderstanding about our role. We must educate our critics about the value that we bring to communications about new therapies. We are our own best advocates in ensuring that critics of our profession are brought out of the wilderness.
Editor-in-Chief
Co-Editors
Managing Editor
Victoria White
Associate Editors
Section Editors
Digital Communication
EMWA News
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
In the Bookstores
Manuscript Writing
Medical Communications/Writing for Patients
Medical Devices
My First Medical Writing
News from the EMA
Out on Our Own
Pharmacovigilance
Regulatory Matters
Regulatory Public Disclosure
Teaching Medical Writing
The Crofter: Sustainable Communications
Veterinary Writing
Editors Emeritus
Lay out Designer
Chris Monk